Viridian Therapeutics, Inc. (NASDAQ: VRDN) is a Healthcare company (Biotechnology) with a market capitalization of $3.4B. The Maz Rating grades it against the other companies in its sector.
Viridian Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $30.06, Viridian Therapeutics, Inc. trades at 128.8x sales and 5.8x book value. Over the last twelve months it generated about $27M of revenue and a net loss of $443M. It runs a gross margin of 93.0%, an operating margin of -1781.4% and a net margin of -1724.1%. It shows return on equity of -69.8%, return on invested capital of -48.8% and a free cash flow yield of -10.1%. On the balance sheet: a debt-to-equity ratio of 0.42 and a current ratio of 14.46. Over the past 52 weeks the share price ranged from $13.18 to $34.29, with a beta of 0.96.
Viridian Therapeutics, Inc. does not currently pay a dividend.
17 Wall Street analyst ratings cover the stock: 15 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.